We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+20.97%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$815M
AUM Growth
+$105M
Cap. Flow
+$27.8M
Cap. Flow %
3.41%
Top 10 Hldgs %
31.52%
Holding
117
New
28
Increased
36
Reduced
33
Closed
18

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$22.9M
2
SDGR icon
Schrodinger
SDGR
+$16.6M
3
FTRE icon
Fortrea Holdings
FTRE
+$14.8M
4
OSCR icon
Oscar Health
OSCR
+$11.4M
5
HCA icon
HCA Healthcare
HCA
+$10.8M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.7M
2
BSX icon
Boston Scientific
BSX
+$14.6M
3
KROS icon
Keros Therapeutics
KROS
+$10.8M
4
MTD icon
Mettler-Toledo International
MTD
+$9.1M
5
HUM icon
Humana
HUM
+$8.28M

Sector Composition

Rank Sector Weight
1 Healthcare 99.46%
2 Industrials 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THC icon
1
Tenet Healthcare
THC
$21.1B
$29.8M 3.66%
283,853
-72,953
-20% -$6.56M
UTHR icon
2
United Therapeutics
UTHR
$23.1B
$29.4M 3.61%
128,199
-33,340
-21% -$7.52M
BSX icon
3
Boston Scientific
BSX
$71.5B
$29.1M 3.58%
425,473
-227,330
-35% -$14.6M
COO icon
4
Cooper Companies
COO
$14.5B
$29M 3.55%
285,399
-15,333
-5% -$1.48M
SDGR icon
5
Schrodinger
SDGR
$1.36B
$27M 3.31%
1,000,014
+594,782
+147% +$16.6M
LLY icon
6
Eli Lilly
LLY
$1.06T
$25M 3.07%
+32,117
New +$22.9M
DXCM icon
7
DexCom
DXCM
$32B
$23.8M 2.92%
171,665
-53,950
-24% -$6.78M
COR icon
8
Cencora
COR
$61.2B
$23.8M 2.92%
97,905
-4,986
-5% -$1.15M
RXST icon
9
RxSight
RXST
$260M
$21.3M 2.61%
412,432
-100,600
-20% -$4.94M
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.82B
$18.7M 2.29%
784,811
+46,222
+6% +$1.03M
NBIX icon
11
Neurocrine Biosciences
NBIX
$16.6B
$18.2M 2.23%
131,951
-8,165
-6% -$1.12M
INSP icon
12
Inspire Medical Systems
INSP
$1.74B
$17.4M 2.14%
81,183
-22,563
-22% -$4.42M
FTRE icon
13
Fortrea Holdings
FTRE
$1.75B
$17.2M 2.11%
+427,804
New +$14.8M
PODD icon
14
Insulet
PODD
$9.79B
$15.6M 1.91%
90,949
+2,274
+3% +$424K
SILK
15
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$15.6M 1.91%
848,897
+303,662
+56% +$4.82M
LBPH
16
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$15M 1.84%
693,144
+263,252
+61% +$5.74M
ABT icon
17
Abbott
ABT
$187B
$13.8M 1.7%
121,689
-35,038
-22% -$4.02M
QGEN icon
18
Qiagen
QGEN
$8.72B
$13.5M 1.66%
305,233
+69,469
+29% +$3.17M
BCYC
19
Bicycle Therapeutics
BCYC
$292M
$13.1M 1.6%
524,253
+211,364
+68% +$4.49M
KNSA icon
20
Kiniksa Pharmaceuticals
KNSA
$5.93B
$12.7M 1.56%
646,163
+30,470
+5% +$595K
APLT
21
DELISTED
Applied Therapeutics
APLT
$12.6M 1.55%
1,854,763
+835,607
+82% +$3.75M
OSCR icon
22
Oscar Health
OSCR
$8.61B
$12.4M 1.52%
+831,283
New +$11.4M
EWTX icon
23
Edgewise Therapeutics
EWTX
$4.73B
$11.9M 1.46%
653,653
+2,028
+0.3% +$32.2K
KROS icon
24
Keros Therapeutics
KROS
$221M
$11.8M 1.45%
178,335
-182,132
-51% -$10.8M
HCA icon
25
HCA Healthcare
HCA
$89.5B
$11.8M 1.44%
+35,283
New +$10.8M
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Parkman Healthcare Partners held 117 positions worth $815M, up 15% from $710M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners deployed $27.8M of net new capital in Q1 2024, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was Eli Lilly: 32,117 shares worth $25M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Boston Scientific, an estimated $14.6M trimmed.

  • Parkman Healthcare Partners's largest Q1 2024 buy was Eli Lilly: 32,117 shares worth $25M.
  • Parkman Healthcare Partners added most to Schrodinger in Q1 2024, an estimated $16.6M increase.
  • Parkman Healthcare Partners's biggest Q1 2024 reduction was Boston Scientific, cutting an estimated $14.6M.
  • Parkman Healthcare Partners fully exited Amgen in Q1 2024, selling an estimated $17.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $815M portfolio in Q1 2024.
  • Parkman Healthcare Partners opened 28 new positions and closed 18 in Q1 2024.
  • Parkman Healthcare Partners's portfolio value rose 15% quarter-over-quarter to $815M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2024, filed 15 May 2024.